Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1400 SGD | 0.00% | 0.00% | -86.92% |
04/07 | Camsing Healthcare Issues Over 60 Million Shares Under Placement Agreements | MT |
25/06 | CamSing Healthcare Addresses Financial Queries Ahead of AGM | MT |
Fiscal Period: January | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -32.5 | -21.61 | -29.97 | -32.65 | -36.77 | |||||
Return on Total Capital | -40.74 | -38.28 | -111.75 | -159.7 | -979.25 | |||||
Return On Equity % | -362.54 | 51.65 | 49.65 | 52.97 | 38.37 | |||||
Return on Common Equity | -362.3 | 51.64 | 49.65 | 53.05 | 38.36 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.4 | 59.35 | 51.7 | 57.51 | 61.46 | |||||
SG&A Margin | 111.47 | 90.23 | 84.63 | 90.55 | 102.31 | |||||
EBITDA Margin % | -48.06 | -27.26 | -31.08 | -31.51 | -39.18 | |||||
EBITA Margin % | -53.07 | -30.88 | -32.93 | -33.03 | -40.85 | |||||
EBIT Margin % | -53.07 | -30.88 | -32.93 | -33.03 | -40.85 | |||||
Income From Continuing Operations Margin % | -74.69 | -14.57 | -24.03 | -39.36 | -56.12 | |||||
Net Income Margin % | -74.69 | -14.55 | -24.01 | -39.41 | -56.1 | |||||
Net Avail. For Common Margin % | -74.69 | -14.55 | -24.01 | -39.41 | -56.1 | |||||
Normalized Net Income Margin | -36.12 | -20.02 | -20.57 | -25.66 | -32.3 | |||||
Levered Free Cash Flow Margin | 53.03 | 29.79 | 18.03 | -8.07 | 12.36 | |||||
Unlevered Free Cash Flow Margin | 55.6 | 31.74 | 19.93 | -3.13 | 19.69 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.98 | 1.12 | 1.46 | 1.58 | 1.44 | |||||
Fixed Assets Turnover | 3.46 | 2.67 | 3.5 | 3.3 | 3.12 | |||||
Receivables Turnover (Average Receivables) | 88.58 | 51.03 | 52.92 | 53.77 | 51.34 | |||||
Inventory Turnover (Average Inventory) | 1.82 | 2.39 | 3.99 | 3.37 | 2.3 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.47 | 0.46 | 0.3 | 0.22 | 0.11 | |||||
Quick Ratio | 0.24 | 0.18 | 0.12 | 0.07 | 0.02 | |||||
Operating Cash Flow to Current Liabilities | 0.56 | 0.4 | 0.13 | -0.09 | 0.03 | |||||
Days Sales Outstanding (Average Receivables) | 4.12 | 7.17 | 6.9 | 6.79 | 7.11 | |||||
Days Outstanding Inventory (Average Inventory) | 200.57 | 153.41 | 91.42 | 108.18 | 158.69 | |||||
Average Days Payable Outstanding | 86.51 | 118.64 | 91.07 | 98.31 | 188.99 | |||||
Cash Conversion Cycle (Average Days) | 118.18 | 41.94 | 7.25 | 16.65 | -23.2 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -458.99 | -172.57 | -117.13 | -117.56 | -89.19 | |||||
Total Debt / Total Capital | 127.86 | 237.79 | 683.89 | 669.61 | -825.38 | |||||
LT Debt/Equity | -135.29 | -33.27 | -48.11 | -15.76 | -3.85 | |||||
Long-Term Debt / Total Capital | 37.69 | 45.84 | 280.91 | 89.77 | -35.67 | |||||
Total Liabilities / Total Assets | 119.57 | 149.46 | 194.93 | 236.38 | 434.18 | |||||
EBIT / Interest Expense | -12.88 | -9.93 | -10.84 | -4.18 | -3.48 | |||||
EBITDA / Interest Expense | -3.72 | -0.36 | -3.04 | -1.3 | -1.1 | |||||
(EBITDA - Capex) / Interest Expense | -4.33 | -0.39 | -3.23 | -1.62 | -1.11 | |||||
Total Debt / EBITDA | -4.88 | -55.33 | -7.66 | -10.74 | -12.05 | |||||
Net Debt / EBITDA | -4.29 | -43.67 | -6.73 | -10.04 | -11.87 | |||||
Total Debt / (EBITDA - Capex) | -4.2 | -50.52 | -7.19 | -8.63 | -11.94 | |||||
Net Debt / (EBITDA - Capex) | -3.69 | -39.87 | -6.32 | -8.07 | -11.76 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -12.85 | -22.14 | -2.81 | 10.36 | -20.5 | |||||
Gross Profit, 1 Yr. Growth % | -9.35 | -20.88 | -15.34 | 22.77 | -15.04 | |||||
EBITDA, 1 Yr. Growth % | 23.4 | -55.84 | 27.43 | 11.87 | -1.14 | |||||
EBITA, 1 Yr. Growth % | 18.52 | -54.69 | 17.11 | 10.71 | -1.69 | |||||
EBIT, 1 Yr. Growth % | 18.52 | -54.69 | 17.11 |